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Abstract Chronic migraine (CM; C15 headache days per
month, C3 months) is associated with a higher prevalence
of comorbidities than episodic migraine (\15 headache
days per month). However, it is unclear whether a similar
pattern exists in Asian patients. To examine this, a retro-
spective matched cohort study was conducted using the
Taiwan National Health Insurance Research Database. CM
cases were deﬁned as patients with at least one neurological
outpatient visit with a primary or secondary ICD-9-CM
(International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation) code of 346.11, diagnosed by neu-
rologists at medical centers during 2007–2008. The study
group was compared with patients suffering from other
migraine subtypes and non-migraineurs in the general
population. Both comparison groups were matched with
CM sufferers at a 4:1 ratio by age, gender, urbanization
level of the residence, income, and hospital setting. Relative
risk (RR) was calculated using conditional logistic regres-
sion. Compared with patients with other migraines (n =
2,226), CM sufferers (n = 681) had a higher risk of
hyperlipidemia (RR = 1.32; P = 0.041), asthma (RR =
1.77; P = 0.007), depression (RR = 1.88; P\0.0001),
bipolar disorder (RR = 1.81; P = 0.022) and anxiety dis-
orders (RR = 1.48; P =\0.0001). Compared with the
non-migraineurs (n = 3,790), CM sufferers (n = 948) had
signiﬁcantly increased risks of cardiovascular disease,
sinusitis, asthma, gastrointestinal ulcers, vertigo and psy-
chiatric disorders by 1.6–3.9-fold. In conclusion, CM is
associated with signiﬁcant comorbidities in Asian patients.
Differences in the comorbidity proﬁles of CM compared
with other migraines have highlightedthat patients with CM
differ not just in terms of headache frequency but also in
other important aspects.
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Introduction
Migraine is a common neurological disorder affecting
9.1 % of the general population in Taiwan [1]. It can be
classiﬁed into two subgroups based on headache frequency,
i.e. episodic migraine (EM;\15 headache days per month)
and chronic migraine (CM, C15 headache days per months,
C3 months) [2, 3]. In the second edition of the International
Classiﬁcation of Headache Disorders (ICHD-2), CM is
listed as a complication of EM and is deﬁned as a diagnosis
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DOI 10.1007/s10194-012-0447-4of migraine with 15 or more headache days per month over
the past 3 months, of which at least eight headache days
meet the criteria for migraine without aura or respond to
migraine-speciﬁc treatment [2, 3].
It is estimated that EM sufferers develop CM at the rate
of 2.5 % per year [4]. The prevalence rate of CM in Taiwan
is estimated to be 1.7 %, with a female to male ratio of
approximately 2:1 [5]. Previous studies have demonstrated
that, when compared to EM, CM was associated with
greater disability, poorer productivity, lower quality of life
and higher healthcare expenditures [6–9].
Migraine has been reported to be associated with various
comorbidities. Previously examined comorbidities include
metabolic syndrome (obesity, stroke, subclinical vascular
brain lesions, coronary artery disease and hypertension),
psychiatric disorders (depression, anxiety, bipolar disorder,
panic disorder and suicide), epilepsy, asthma and other
disorders [10]. Recently, the American Migraine Preva-
lence and Prevention (AMPP) study, a large, longitudinal,
population-based survey involving 24,000 patients with
headaches, demonstrated that patients with CM differed
from the EM population in several aspects in terms of the
sociodemographic and comorbidity proﬁles [11]. However,
it is unclear if a similar pattern exists in Asian patients. The
present study therefore aims to provide insight into the
prevalence of comorbidities in patients with CM in Taiwan.
Methods
Study design and data source
A population-based retrospective matched cohort study
was conducted utilizing the National Health Insurance
Research Database (NHIRD) in Taiwan. The National
Health Insurance (NHI) is a social health insurance pro-
gram that covers nearly 99 % of the population for com-
prehensive health care in Taiwan. The NHIRD contains all
beneﬁt claims and was established by the Taiwan National
Health Research Institute (NHRI), in cooperation with the
Bureau of NHI, for research purposes.
In this study, patients with migraine were sampled from
the NHIRD inpatient and outpatient expenditure claims
data ﬁles from the year 2006 to 2009. These ﬁles contained
the birth date and gender of the patient, services provided,
principal and secondary diagnosis codes, and itemized
expenditure on the various types of services, such as phy-
sician consultation, drugs and prescription services, and in-
hospital care. One million NHI beneﬁciaries, representative
of the non-migraineurs in Taiwan, were taken from a
similar database, from March 1995 when the NHI was put
into effect, until the end of 2009.
All personal identiﬁers were encrypted by the NHRI
before they were released to the researchers. Thus conﬁ-
dentiality was assured according to the data regulations of
the Bureau of NHI, and the approval of the Institutional
Review Board was not required.
The study cohort and the comparison cohorts
Patients with migraine were either assigned as patients with
CM or patients suffering from migraine other than CM. The
study cohort consisted of CM cases, deﬁned as patients with
at least one neurological outpatient visit with primary or
secondary 2007 ICD-9-CM (International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation) code of
346.11 (common migraine with intractable migraine so
stated), and who were diagnosed by a certiﬁed neurologist
at a medical centre between 2007 and 2008 (n = 1,101). As
there was no known ICD-9-CM code for CM diagnosis at
that time, these criteria were used to capture CM cases more
accurately, based on our knowledge of where the patients
were treated.
Patients suffering from migraine other than CM were
deﬁned as patients who had at least one outpatient visit with
primary or secondary ICD-9-CM codes for migraine
346.XX other than 346.11 between 2007 and 2008, and who
had never been diagnosed with migraine prior to 1 January
2007. These included 2007 ICD diagnostic codes for clas-
sical migraine without intractable migraine (346.00), com-
mon migraine without intractable migraine (346.10),
variants of migraine without intractable migraine (346.20),
other forms of migraine without intractable migraine
(346.80) and migraine unspeciﬁed without intractable
migraine (346.90). Any cases with a diagnostic code
involving intractable migraine were excluded. This group of
patients formed our ﬁrst comparison cohort and was mat-
ched with the study cohort at a 4:1 ratio by age, gender and
hospital setting. The index date was deﬁned as the date
when the study cases were ﬁrst diagnosed as CM and when
patients with migraine other than CM were diagnosed.
The second comparison cohort was drawn from the 2005
to 2009 database of 1,000,000 NHI beneﬁciaries who were
never diagnosed with migraine. They were matched with
the study sample at a 4:1 ratio by age, gender, urbanization
level of the residence, and income (n = 3,790). The date
when the study cases were diagnosed with CM was
assigned as the index date for both groups.
A total of 420 CM cases that were not matched with
other migraine sufferers and 153 CM cases that were not
matched with non-migraineurs were lost from the study.
The ﬁnal sample sizes obtained for the matched cohorts
were 681 and 948, respectively.
312 J Headache Pain (2012) 13:311–319
123Deﬁnition of urbanization level of the residence
According to Taiwan National Health Research Institute
publications, urbanization levels in Taiwan are divided into
seven strata, with level 1 referring to the ‘‘most urbanized’’
and level 7 referring to the ‘‘least urbanized’’ communities.
As there were very small numbers of CM cases in levels 4,
5, 6 and 7, these four levels were combined into level 4–5
and level 6–7 groups [12].
Deﬁnition of comorbidity
Patients who made at least three claims for outpatient visits
or one claim for hospitalization within 1 year after the
index date with principal/secondary diagnoses of the fol-
lowing diseases were considered probable comorbidities
associated with CM. These diseases can generally be cat-
egorized as:
1. metabolic syndrome, including hypertension (ICD-9-
CM codes 401.0, 401.1, 401.9, 402–405, 437.2), diabe-
tes (ICD-9-CM code 250), hyperlipidemia (ICD-9-CM
codes 272.0–272.4), heart disease (ICD-9-CM codes
410–429), and ischemic strokes (ICD-9-CM codes 433,
434 and 436)
2. respiratory diseases, including sinusitis (ICD-9-CM
codes 461, 473), asthma (ICD-9-CM code 493), and
emphysema or chronic obstructive pulmonary disease
(COPD) (ICD-9-CM codes 490–492, 496)
3. gastrointestinal disorders, including peptic ulcer (ICD-
9-CM codes 531–534), stomach or duodenal ulcers
(ICD-9-CM codes 536–537) and gastrointestinal hem-
orrhage (ICD-9-CM codes 578)
4. neurological disorders, including epilepsy (ICD-9-CM
code 345) and vertigo (ICD-9-CM codes 780.4, 386)
5. psychiatric disorders, including drug abuse (ICD-9-CM
codes 292, 304, 305.1–305.9), depression (ICD-9-CM
codes 296.2, 296.3, 296.9, 300.4, 309.0, 309.1, 311),
bipolar disorder (ICD-9-CM codes 296.0, 296.1,
296.4–296.7, 296.80, 296.89), anxiety disorders (ICD-
9-CM codes 300.0–300.3, 300.5–300.9, 309.2, 309.4,
309.81, 313.0), panic disorder (ICD-9-CM codes
300.01, 300.21, 300.22), obsessive compulsive disorder
(ICD-9-CM code 300.3), suicide (ICD-9-CM codes
E950–E959) and insomnia (ICD-9-CM codes 307.41,
307.42, 307.49, 780.50, 780.52, 780.55, 780.56,
780.59).
Statistical analysis
Chi-square tests were performed to analyze the sociode-
mographic characteristics of the sample groups. Prevalence
of comorbidities within 1 year after the index date and their
RRs with 95 % conﬁdence interval (CI) were calculated
using conditional logistic regression analysis. The RRs
were adjusted for age, gender, urbanization level of the
residence and income. Each comorbid disease was com-
pared independently. A P value of\0.05 was considered to
be statistically signiﬁcant. All analyses were performed
using the SAS system for Windows, version 9.2 (SAS
Institute, Cary, NC).
Results
Table 1 shows the demographic characteristics of the study
group and the two comparison cohorts. All demographic
characteristics were well matched in the two comparison
cohorts. The majority of CM cases were female (approxi-
mately 80 %) and were mostly in the young adults and
middle-aged groups, ranging from age 20 to 59 years.
Table 2presentsthedistributionandRRofcomorbidities
among patients with CM and the two comparison cohorts.
Compared with other migraines, CM was associated with a
signiﬁcantly higher risk of hyperlipidemia (RR = 1.32;
95 % CI = 1.01–1.72), asthma (RR = 1.77, 95 % CI =
1.17–2.69), depression (RR = 1.88, 95 % CI = 1.51–
2.33), bipolar disorder (RR = 1.81, 95 % CI = 1.09–2.99)
and anxiety disorders (RR = 1.48, 95 % CI = 1.19–1.83).
NosigniﬁcantassociationswereseenbetweenCMandother
cardiovascular, respiratory, gastrointestinal, neurological or
psychiatric comorbidities compared to other migraines.
Compared with non-migraineurs, CM sufferers had a
1.6–3.9-fold risk of comorbidities, including hypertension
(RR = 1.64, 95 % CI = 1.35–1.99), hyperlipidemia
(RR = 1.84, 95 % CI = 1.45–2.32), heart disease (RR =
1.73, 95 % CI = 1.36–2.21), ischemic stroke (RR = 1.81,
95 % CI = 1.18–2.78), sinusitis (RR = 1.77, 95 % CI =
1.41–2.21), asthma (RR = 2.27, 95 % CI = 1.59–3.25),
emphysema or COPD (RR = 1.73, 95 % CI = 1.16–2.58),
peptic ulcers (RR = 2.39, 95 % CI = 1.93–2.95), duode-
nal ulcers (RR = 2.31, 95 % CI = 1.84–2.91), vertigo
(RR = 2.49, 95 % CI = 1.81–3.43), and psychiatric dis-
orders, including depression (RR = 3.83, 95 % CI =
3.14–4.68), bipolar disorder (RR = 3.88, 95 % CI =
2.39–6.29),anxietydisorders(RR = 2.89,95 %CI = 2.37–
3.52), panic disorder (RR = 2.85, 95 % CI = 1.62–5.00),
and insomnia (RR = 2.28, 95 % CI = 1.87–2.78). Sig-
niﬁcant associations were not found between CM and
diabetes, gastrointestinal hemorrhage, epilepsy and obses-
sive compulsive disorder.
Additionally, we also compared the RR of comorbidities
between the two comparison cohorts. Compared with non-
migraineurs, the other migraine sufferers had a 1.2–1.9-
fold risk of comorbidity. In general, the RRs were
numerically lower for the other migraine versus
J Headache Pain (2012) 13:311–319 313
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non-migraineurs, except for epilepsy and ischemic stroke.
Other migraine was associated with a signiﬁcantly higher
risk of epilepsy (RR = 1.75, 95 % CI = 1.21–2.51) and
ischemic stroke (RR = 1.85, 95 % CI = 1.41–2.42).
Discussion
The present study found that patients with CM had a sig-
niﬁcantly higher risk of hyperlipidemia (RR = 1.32),
asthma (RR = 1.77), and anxiety disorders, depression and
bipolar disorder (RR = 1.48–1.88) than those with other
migraines. However, the prevalence of gastrointestinal,
neurological and metabolic (other than hyperlipidemia)
comorbidities in patients with CM and patients with other
migraines were similar. The study also conﬁrmed that CM
posed a higher risk for hypertension (RR = 1.64), hyper-
lipidemia (RR = 1.84), heart disease (RR = 1.73) and
ischemic stroke (RR = 1.81) compared with non-migrai-
neurs. The RR was also signiﬁcantly higher for sinusitis
(RR = 1.77), asthma (RR = 2.27), and emphysema or
COPD (RR = 1.73), and CM sufferers were also found to
be more likely to develop peptic ulcer (RR = 2.39), stom-
ach/duodenal ulcer (RR = 2.31) and vertigo (RR = 2.49).
The RR for psychiatric disorders in patients with CM was
3.83 for depression, 3.88 for bipolar disorder, 2.89 for
anxiety disorders, 2.85 for panic disorder and 2.28 for
insomnia.
Metabolic syndrome
Metabolic syndrome is a constellation of risk factors that
contribute to the development of cardiovascular disease,
cerebrovascular disease and diabetes mellitus. Scher et al.
[13] reported that migraineurs had an increased risk of
hypertension (odds ratio, OR = 1.63, 95 % CI = 1.2–2.1),
elevated total cholesterol ([240 mg/dL) (OR = 1.22, 95 %
CI = 1.0–1.5), and were more likely to have a parental
history of early myocardial infarction (OR = 2.25, 95 %
CI = 1.0–5.1). Kurth et al. [14] also found that women with
any history of migraine had an increased risk of myocardial
infarction (hazard ratio, HR = 1.41, 95 % CI = 1.03–1.91)
and coronary revascularization (HR = 1.35, 95 %
CI = 1.09–1.67). Results from a meta-analysis by Schu ¨rks
et al. [15] showed that patients with migraine were almost
Table 1 Sociodemographic characteristics of patients with chronic migraine (CM) and the two comparison groups
CM cases
(N = 681)
Comparison cohort:
cases with other
migraine (N = 2,226)
P value CM cases
(N = 948)
Comparison cohort:
non-migraine population
(N = 3,790)
P value
n % n % n % n %
Age (years)
\20 40 5.87 102 4.58 0.348 70 7.38 280 7.39 1.000
20–40 273 40.09 941 42.27 382 40.30 1,526 40.26
40–60 292 42.88 964 43.31 356 37.55 1,424 37.57
C60 76 11.16 219 9.84 140 14.77 560 14.78
Gender
Male 146 21.44 446 20.04 0.426 234 24.68 934 24.64 0.980
Female 535 78.56 1,780 79.96 714 75.32 2,856 75.36
Urbanization level
1 (high) 259 38.03 934 41.96 0.101 282 29.75 1,128 29.76 1.000
2 229 33.63 768 34.50 305 32.17 1,220 32.19
3 82 12.04 252 11.32 151 15.93 604 15.94
4–5 70 10.28 187 8.40 109 11.50 436 11.50
6–7 35 5.14 79 3.55 100 10.55 400 10.55
Missing 6 0.88 6 0.27 1 0.11 2 0.05
Premiums (NT$)
[43,900 79 11.60 242 10.87 0.722 103 10.86 412 10.87 1.000
30,301–43,900 55 8.08 187 8.40 81 8.54 324 8.55
21,001–30,300 74 10.87 274 12.31 105 11.08 420 11.08
B21,000 67 9.84 241 10.83 98 10.34 392 10.34
Fixed 406 59.62 1,282 57.59 561 59.18 2,242 59.16
RR relative risk, CI conﬁdence interval, SD standard deviation
314 J Headache Pain (2012) 13:311–319
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123twice as likely to have ischemic stroke (pooled RR = 1.73,
95 % CI = 1.31–2.29), especially patients suffering from
migraine with aura. We also observed a higher prevalence
of hypertension, hyperlipidemia, heart disease and ischemic
stroke in patients with CM compared to the non-migrai-
neurs. As the methodology used in our study only allowed
assessment of comorbidities within the ﬁrst year of the
index date, a longer duration of follow-up would be nec-
essary to assess the correlation of CM and metabolic
syndrome.
Respiratory diseases
Findings from a Norwegian study indicated that migrainous
headaches were related to asthma, hay fever and chronic
bronchitis and this association increased with headache
frequency, particularly in migraines occurring 15 days or
more per month [16]. Similarly, the AMPP study showed
that asthma (OR = 1.53, 95 % CI = 1.27–1.84) was more
likely to be reported by those with CM compared with
episodic migraineurs [11]. Our study conﬁrmed that CM
displayed a higher risk of asthma compared with patients
with other migraine (RR = 1.77). The prevalence of
sinusitis (RR = 1.77), asthma (RR = 2.27) and COPD,
including emphysema (RR = 1.73) were signiﬁcantly
higher than seen in non-migraineurs. Davey et al. [17]
reported a similar RR of asthma in patients with migraine
(RR = 1.59, 95 % CI = 1.54–1.65), and COPD (RR =
1.22, 95 % CI = 1.12–1.34), although the diagnostic codes
used for migraine in the Davey study differed from those
used in our present study. We found no signiﬁcant associ-
ation of CM with other respiratory disorders, such as
sinusitis or COPD (including emphysema), when looking at
the CM group compared with the other migraine group;
however, this should be conﬁrmed with a longitudinal fol-
low-up in future studies since asthma is a known risk factor
for COPD and other pulmonary disorders.
Gastrointestinal disorders
There are few studies that report an association between
migraine and gastrointestinal disorders. Ferrari et al
reported that ‘gastrointestinal diseases’ was the second
most frequent comorbid disorder in CM sufferers [18].
Results from the present study indicated that patients with
CM experienced a higher risk of peptic ulcer (RR = 2.39)
and duodenal ulcer (RR = 2.31) compared with the non-
migraineurs. Stress is known to provoke the onset of
clinically symptomatic migraine, amplifying migraine
attack intensity and the duration of the episode [19].
Additionally, stress is often considered a risk factor for
upper gastrointestinal tract disease [20]. The high preva-
lence of CM and peptic ulcer disease comorbidity in our
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123study cohort may be attributed to their shared etiology.
Moreover, the increased risk of peptic ulcer and duodenal
ulcer may not be caused by migraine itself but by the
consequence of increased intake of non-steroidal anti-
inﬂammatory drugs for pain control [8, 21].
Neurological disorders
The pathophysiological mechanism and clinical features of
epilepsy and migraine are postulated to be the same, and
one may precipitate, follow or occur concurrently with the
other [22]. However, published evidence of the relationship
between migraine and epilepsy is controversial, mainly
because of the variability of methodology and migraine
classiﬁcation. While some studies have conﬁrmed a
comorbid occurrence of migraine among epilepsy patients,
others have reported differently [23–26]. Results of our
study indicated that there was no signiﬁcant association
between CM and epilepsy.
Our results showed a higher risk of vertigo in patients
with CM than in the non-migraineurs (RR = 2.49, 95 %
CI = 1.81–3.43). This was consistent with a previous
ﬁnding by Eggers et al. [27] indicating a strong relationship
between vertigo and migraine [27]. Calhoun et al. [28]
suggested that vertigo may be considered as an independent
entity occurring concurrently in patients with migraine, or
as a presenting symptom of migraine itself, particularly in
migraineurs with aura. Phillips et al. [29] argued that true
vertigo occurring together with migraine is rare; ‘‘dizzi-
ness’’ is often mistaken for vertigo, but these entities differ
clinically and biologically as vertigo is a hallmark of inner
ear disease. Here, we see the importance of differentiating
peripheral vestibular vertigo from migrainous vertigo while
reviewing available literature on this topic.
Psychiatric disorders
The relationship between depression and migraine appears
to be bidirectional, where one disease entity increases the
risk of the development of the other, and vice versa. For
example, Breslau et al. [30] found that patients with
migraine were predisposed to an increased risk of depres-
sion (OR = 5.8) and patients with depression were at
higher risk of developing migraine (OR = 3.4), when
compared with patients who suffered from other severe
headaches or none at all30. Previous studies also showed
that migraine was associated with anxiety disorder (OR =
3.9–5.3) [31, 32], panic disorder (OR = 3.7) [33], bipolar
disorder (OR = 2.4–7.3) [34] and suicide attempts
(OR = 1.6–3.0) [35]. The AMPP study showed that
patients with CM were more likely to suffer from anxiety
(OR = 1.8), depression (OR = 2.0) and bipolar disorder
(OR = 1.56) than those with episodic migraine [11].
Results from the present study conﬁrmed that psychiatric
disorder had a greater likelihood to co-exist with CM than
with other migraines. A higher risk of psychiatric disorder
was evident in patients with CM when compared with the
non-migraineurs. Finally, the present study also conﬁrmed
ﬁndings from previous studies that reported an association
between insomnia and migraine [35–37]. The RR for sui-
cide in patients with CM was not obtained in our present
study due to lack of data, but a population survey con-
ducted by Wang et al. [38] among adolescents in Taiwan
demonstrated that CM with aura was an independent factor
for suicide risk, but not migraine without aura. Although
our study found no signiﬁcant link between CM sufferers
and illicit drug abuse, analgesia overuse and substance
dependence have been noted to be common in patients with
CM [39, 40].
The AMPP study by Buse et al. [11] reported that, in
addition to lower socioeconomic status and functioning,
patients with CM were more likely to have heart disease
(OR = 1.4) and cardiac risk factors, such as hypertension,
high cholesterol and obesity (OR = 1.2–1.5), stroke
(OR = 1.7), ulcers (OR = 1.9) and respiratory diseases,
such as allergies, asthma, sinusitis, bronchitis and COPD
(OR = 1.4–2.0). Chronic pain disorders and psychiatric
disorders such as depression, anxiety and bipolar disorders
were more likely to be reported in patients with CM than in
those with EM. There was no signiﬁcant association with
diabetes and epilepsy in patients with CM or EM. It should
be noted that while Buse et al. looked at the relationship
between migraine frequency and comorbidities, our study
design looked at the comorbidity proﬁle of patients with
CM versus other migraine subtypes and non-migraineurs.
Nevertheless, we were able to conﬁrm the ﬁndings by Buse
et al. that high rates of comorbid diseases were indeed
associated with CM, especially hypertension, high choles-
terol, heart disease, sinusitis, asthma, COPD, depression,
and anxiety and bipolar disorders. Both studies showed no
relationship between CM and diabetes, regardless of fre-
quency or subtypes. Our study found that peptic ulcer
disease, vertigo, panic disorder and insomnia were signif-
icantly evident in patients with CM compared with non-
migraineurs. In contrast to the report by Buse et al., our
results did not show the association between CM and
ischemic stroke.
CM versus non-migraineurs, and other migraineurs
versus non-migraineurs
A comparison of the other migraine patients with non-
migraineurs concerning comorbidity would be helpful to
decide if the CM sufferers have a different proﬁle as other
migraines. In general, the RRs are numerically higher for
the former than the latter except for epilepsy and ischemic
J Headache Pain (2012) 13:311–319 317
123stroke. However, the reason for this is unknown. Therefore,
the data suggest that CM had a higher comorbidity than
other migraineurs when compared to controls.
The strengths of this study were mainly attributed to (1)
the large population-based sample size to power the study,
(2) the comprehensiveness of data within the NHIRD, (3)
the use of speciﬁc ICD diagnostic codes to deﬁne comorbid
diseases and (4) the control of confounding variables by
matching the study groups according to age, sex and
socioeconomic status. The last variable in this study was
especially matched by controlling the level of urbanization
and personal incomes. Since these factors are associated
with medical seeking behaviors, which may in turn inﬂu-
ence the chance of disease diagnoses, our comorbidity
results are, therefore, more robust for a claim-based data-
set. Several limitations should be taken into account when
interpreting the results of this study. Firstly, the prevalence
of comorbidities was assessed by diagnostic coding in an
administrative claims database, and reporting bias may be
present due to either over-reporting or under-reporting of
the disease. Secondly, there is also a possibility of report-
ing bias due to our sampling method. Thirdly, because the
primary and secondary diagnoses of CM and other medical
conditions were not analyzed separately from the database,
caution should be exercised when interpreting their asso-
ciation either as distinct concurrent diseases, or as events
preceding or following the index disease. Furthermore, the
matching was not complete between CM and EM. Finally,
there were no corresponding ICD-9-CM codes for CM until
2011. To further deﬁne such cases, in this study we used
ICD-9 CM code 346.11 (common migraine with intractable
migraine so stated) and we only selected cases diagnosed
by neurologists at the medical centers. With the new 2011
ICD-9-CM code for CM, our ﬁndings may be open to
assessment bias due to overlapping selection criteria when
deﬁning CM in this study. With the newly improved
diagnostic classiﬁcation for CM, we hope to reﬁne our
assessment of CM and its related comorbidities in future
studies.
Conclusion
Despite these limitations, ﬁndings of increased RR for CM
in the present study were similar to those reported in other
studies. The present study conﬁrmed the association
between CM and hyperlipidemia, asthma and psychiatric
disorders when compared with other migraines, as well as
its association with certain metabolic syndrome, respira-
tory, neurological and psychiatric disorders when com-
pared with the non-migraineurs.
The presence of a comorbid disease may alter the nature,
progression and response to treatment of CM and hence
should be addressed simultaneously by treating the under-
lying etiology or implementing preventive measures, where
applicable. It is also important for clinicians to recognize
CM as a condition that is distinct from other migraines and
to formulate a management plan that aims to improve
patient outcomes, treatment adherence and quality of life.
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